Ac2-26

Ac2-26 is the N-terminal peptide of annexin 1, and has anti-inflammatory activity. Ac2-26 induces a decrease in IKKβ protein in lysosomes by chaperone-mediated autophagy (CMA) . Ac2-26 ameliorates lung ischemia-reperfusion injury. Ac2-26 also inhibits airway inflammation and hyperresponsiveness in an asthma rat model[1][2][3][4].

Product Specifications

CAS Number

[151988-33-9]

UNSPSC

12352209

Target

Annexin A; NF-κB

Type

Peptides

Related Pathways

Cytoskeleton; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ac2-26.html

Purity

99.33

Solubility

DMSO : 20 mg/mL (ultrasonic; adjust pH to 2 with HCl) |H2O : 7.14 mg/mL (adjust pH to 10 with NaOH)

Smiles

OC(C=C1)=CC=C1C[C@@H](C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](C(C)C)C(N[C@H](C(O)=O)CCCCN)=O)=O)=O)=O)=O)NC([C@H](CCC(O)=O)NC([C@H](CCC(N)=O)NC([C@H](CCC(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CC(N)=O)NC([C@H](CCC(O)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC2=CC=CC=C2)NC([C@@H](NC([C@H](C)NC([C@H](CCC(N)=O)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@@H](NC([C@H](CCC(O)=O)NC([C@H](CO)NC([C@H](C(C)C)NC([C@H](CCSC)NC([C@H](C)NC(C)=O)=O)=O)=O)=O)=O)CC3=CC=CC=C3)=O)=O)=O)=O)=O)CC4=CNC5=CC=CC=C45)=O)=O)=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C141H210N32O44S

Molecular Weight

3089.43

References & Citations

[1]Wang LM, et al. Annexin 1-derived peptide Ac2-26 inhibits eosinophil recruitment in vivo via decreasing prostaglandin D₂. Int Arch Allergy Immunol. 2011;154 (2) :137-48.|[2]Liu L, et al. Ac2-26 Induces IKKβ Degradation Through Chaperone-Mediated Autophagy Via HSPB1 in NCM-Treated Microglia. Front Mol Neurosci. 2018 Mar 15;11:76.|[3]Gong J, et al. Ac2-26 ameliorates lung ischemia-reperfusion injury via the eNOS pathway. Biomed Pharmacother. 2019 Sep;117:109194.|[4]Luo Z, et al. Annexin-1 Mimetic Peptide Ac2-26 Suppresses Inflammatory Mediators in LPS-Induced Astrocytes and Ameliorates Pain Hypersensitivity in a Rat Model of Inflammatory Pain. Cell Mol Neurobiol. 2020 May;40 (4) :569-585.|[5]Zheng Y, et al. Annexin A1 (Ac2-26) -dependent Fpr2 receptor alleviates sepsis-induced acute kidney injury by inhibiting inflammation and apoptosis in vivo and in vitro. Inflamm Res. 2023 Feb;72 (2) :347-362.|[6]Qin CX, et al. Cardioprotective Actions of the Annexin-A1 N-Terminal Peptide, Ac2-26, Against Myocardial Infarction. Front Pharmacol. 2019 Apr 3;10:269.

Shipping Conditions

Blue Ice

Storage Conditions

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

Scientific Category

Peptides

Clinical Information

No Development Reported

Citation 01

Biol Reprod. 2025 Mar 26:ioaf060.|Cancer Cell. 2023 May 8;41 (5) :903-918.e8.|Exp Cell Res. 2026 Jan 1;454 (1) :114825.|Nat Nanotechnol. 2025 Aug 11.|Signal Transduct Target Ther. 2024 Aug 23;9 (1) :218.|iScience. 2023 Oct 6;26 (11) :108153.|Mater Today Bio. 2025 Mar 20:32:101690.|World J Gastroenterol. 2023 Jun 14;29 (22) :3422-3439.